Makes a sterile acoustic coupling fluid matched to the acoustic properties of brain tissue, so surgeons can see residual tumor on intraoperative ultrasound during resections. FDA granted it Breakthrough Device designation in July 2025 and accepted its 510(k) for review in October 2026.
One email, every morning
THE MORNING BRIEF
New clearances, funding rounds and regulatory moves for device founders, and every new how-to guide and template as it lands. No noise, no login.
✓
You're in. The next morning brief lands in your inbox.
No Spam. Unsubscribe anytime.